Olaparib After Response to Trabectedin-pegylated Liposomal Doxorubicin in Recurrent Ovarian Carcinoma

NCT03470805 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Cancer

Interventions

DRUG: Olaparib

Sponsor

Grupo Español de Investigación en Cáncer de Ovario

Collaborators

[object Object]
[object Object]